Snapshot from Apr 21, 2026 at 07:00 UTC. For live data and tracking: View Live
Entities / NicOx
Company

NicOx

Tracked across 1 events · 7 articles · First seen Feb 10, 2026 · Last active Feb 24, 2026

Sentiment
70
Attention
4
Events
1
Relationships
4
Live sentiment trends, attention charts, and prominence tracking available on the NewsDesk Dashboard
Events (1)
4 70
Business
NicOx NCX 470 Phase 3 Data Positive
NicOx announced positive Phase 3 data for its drug candidate NCX 470, which is expected to significantly lower intraocular pressure in glaucoma patients. This positive data validates their development program and could lead to a New Drug Application in the U.S. and China, potentially boosting the company's market position and stock value.
Feb 10, 2026 · 7 articles
Relationships (4)
Doug Hubatsch Chief Scientific Officer ↔ NicOx Doug Hubatsch is the Chief Scientific Officer of NicOx.
Bausch & Lomb exclusive licensee ↔ NicOx Bausch & Lomb is the exclusive worldwide licensee for NicOx's product VYZULTA.
Harrow licensee ↔ NicOx Harrow, Inc. licenses ZERVIATE from NicOx in the U.S.
Glaukos Corporation partner ↔ NicOx NicOx has a preclinical research program with Glaukos Corporation on NCX 1728.
NEWSDESK
Track NicOx live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.